DPP4 inhibitor

ApprovedSmall molecule

AstraZeneca

DPP4 inhibitor is one of 48 small molecule programs targeting Coronary Atherosclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary AtherosclerosisActive, not recruiting

Type 2 DiabetesActive, not recruiting

Coronary AtherosclerosisPreclinical

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

DPP4 inhibitor

AstraZeneca

Approved

1 2

NOVOLIN R

Novo Nordisk

Preclinical

5 3

Glargine

Eli Lilly

Preclinical

8 4

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 5

Aurlumyn

BBTG International Inc.

Preclinical

1 6

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 7

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 8

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 9

Lovaza

AstraZeneca

Preclinical

1 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Fatty Liver1 trial

Fatty Liver Study in Patients With Type II Diabetes

Terminated·TThe University of Texas Medical Branch, Galveston·Phase 4·NCT02365233·5 enrolled

Coronary Atherosclerosis1 trial

DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy

Completed·TThe Catholic University of Korea··NCT04825795·4,007 enrolled

Type 2 Diabetes1 trial

The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin

Unknown status·MMackay Memorial Hospital·Phase 4·NCT03458715·120 enrolled

RCT1 trial

Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)

Completed· AstraZeneca logo

AstraZeneca··NCT06099067·239,990 enrolled

Unspecified1 trial

Study of Sulphonylurea Synergy With DPP4 Inhibitors

Completed·UUniversity of Dundee·N/A·NCT04192292·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for DPP4 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DPP4 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DPP4 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

DPP4 inhibitor

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Fatty Liver1 trial

Coronary Atherosclerosis1 trial

Type 2 Diabetes1 trial

RCT1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News